12 April 2024

INOVIQ ShareCafe Investor Presentation

Melbourne, Australia, 12 April 2024: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) advises that CEO Dr Leearne Hinch will provide an investor presentation via ShareCafe - Hidden Gems Webinar on the 12 April 2024.

The details and link to register for the webinar are provided below:

Date:	Friday, 12 April 2024
Time:	12:30 PM AEST
Registration:	https://us02web.zoom.us/webinar/register/WN_88KbKenzQ8GJ1wJMnFRNkg

Authorised for release by Company Secretary, Mark Edwards.

- ENDS -

FURTHER INFORMATION

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

David Williams
Chairman
E dwilliams@kidder.com.au
M +61 414 383 593

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours. For more information on INOVIQ, visit www.inoviq.com.

For personal use only

For personal use only

ShareCafe
Investor Presentation

12 April 2024

Next-generation diagnostics and therapeutics

INOVIQ

ASX: IIQ

Important Notice & Disclaimer

For personal use only

This presentation has been prepared by INOVIQ Limited ("INOVIQ" or the "Company") based on information available to it as at the date of this presentation. This presentation contains general and background information about the Company's activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision and does not contain all information about the Company's assets and liabilities, financial position and performance, profits and losses, prospects, and the rights and liabilities attaching to the Company's securities necessary to make an investment decision. The information in this presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), available at www.asx.com.au. The information in this presentation is based on the Company's own information and estimates and has not been independently verified. The Company is not responsible for providing updated information and assumes no responsibility to do so. Any investment in the Company should be considered speculative and there is no guarantee that they will make a return on capital invested, that dividends would be paid, or that there will be an increase in the value of the investment in the future.

This Presentation may contain certain "forward-looking statements" that are based on management's beliefs, assumptions and expectations and on information currently available to management. The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings, financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including INOVIQ or any of its advisers). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this Presentation will actually occur. Actual operations, results, performance, targets or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based.

Nothing contained in this Presentation constitutes investment, legal, tax or other advice. This Presentation does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company's prospects.

You should note that any past performance is given for illustrative purposes only and should not be relied on as (and is not) an indication of the Company's views on its future financial performance or condition. Past performance, including past share price performance, of INOVIQ cannot be relied on as an indicator of (and provides no guidance as to) future performance including future share price performance.

INOVIQ overview | Next generation diagnostics and therapeutics

For personal use only

Exosome powered

Next-gen exosome solutions for earlier detection and treatment of cancer

Disruptive technology

Proprietary exosome and SubB2M technologies underpinning pipeline

Products in market

Exosome research tools and bladder cancer test in-market and generating revenues

Deep pipeline

Differentiated, multi-stage exosome research tool, diagnostic and therapeutic pipeline for cancer

Excellent clinical data

Data showing superior exosome isolation, accurate cancer detection and in vitro cancer killing activity

Partnering for growth

Global partners for sales of EXO-NET and development of exosome diagnostics to accelerate growth

Financial information (ASX:IIQ)	
Ordinary shares[1]	92,018,702
Unlisted options[1]	8,955,756
52-week H/L[1]	A$0.94-0.47
Share price[1]	A$0.59
Market capitalisation[1]	A$54.3m
Cash at bank[2]	A$5.97m
Major shareholders (as at 31 December 2023)	
Merchant Funds Mgt Pty Ltd	14.2%
David Williams	5.4%

IIQ 12-month share price performance



1. As at 11 Apr 2024; 2. Cash at 31 Dec 2023 (ASX: 31 Jan 2024)

Board & Management

For personal use only

DAVID WILLIAMS
Non-Executive Chairman

Experienced biotechnology director and investment banker with extensive strategic, corporate and financial markets experience.

Currently Chairman PolyNovo Ltd, Chairman of RMA Global Ltd and Managing Director of corporate advisory firm Kidder Williams Ltd.

Previously Chairman and major shareholder Medical Developments International Ltd.
Major shareholder Healthily Pty Ltd.

DR GEOFF CUMMING
Non-Executive Director

Healthcare and biotechnology director with extensive diagnostics industry experience.

Previously Managing Director Roche Diagnostic Systems (Oceania), MD/CEO Biosceptre international Ltd and MD/CEO of Anteo Diagnostics Ltd.

Currently NED AnteoTech Ltd.

MAX JOHNSTON
Non-Executive Director

Healthcare industry director and international business leader with extensive experience across medtech, pharmaceuticals, consumer healthcare and consumer goods.

Previously President and CEO of Johnson & Johnson Pacific, Chairman of AusCann Ltd, NED of PolyNovo Ltd, Medical Developments International Ltd, Tissue Repair Ltd and CannPal Animal Therapeutics Ltd.

PHILIP POWELL
Non-Executive Director

Healthcare industry director and chartered accountant with extensive investment banking experience specialising in capital raisings, IPOs, mergers and acquisitions and other transactions across pharma, food and agriculture.

Previously at OAMPS Ltd and Arthur Andersen, and NED at Polynovo Ltd and Medical Developments International Ltd.

Currently NED RMA Global Ltd.

DR LEEARNE HINCH BVMS MBA
Chief Executive Officer

Biotechnology CEO with a track record in corporate development, capital raising, product development, commercialisation and licensing.

Past leadership and consulting roles in ASX-listed biotechnology, multinational and private companies in diagnostics, devices, therapeutics and animal health including Eustralis Pharmaceuticals, HealthLinx, OBJ, Holista Colltech, Virbac and Mars.

DR GREG RICE PhD MHA
Chief Scientific Officer

Internationally recognised, award-winning scientist with over 35 years' experience and a successful track record in oncology research, exosome science, biomarker discovery, and diagnostics development.

Previous leadership roles in academia and industry including at The University of Queensland Centre for Clinical Research, Baker Heart Institute, University of Melbourne, Monash University and HealthLinx.

MARK EDWARDS BAcc CA
CFO & Company Secretary

Experienced finance executive with expertise in financial leadership and management, corporate governance, investor relations and corporate transactions.

Previous senior roles in ASX listed pharmaceutical, medical device and healthcare companies, including Medical Developments International and Cogstate.

INOVIQ

Business model | Research tools, diagnostics and therapeutics for cancer

For personal use only

Core technologies

Exosome platform
Proprietary exosome isolation technology for research, diagnostics and therapeutics

SubB2M technology
Novel technology for enhanced cancer diagnosis

Business segments

Research tools

EXO-NET exosome isolation for biomarker discovery and diagnostics development

Diagnostics

Exosome tests for cancer and neurodegenerative disease

SubB2M tests for breast and ovarian cancer

hTERT test for bladder cancer

Therapeutics

Early-stage exosome therapeutics for cancers

In-market | **Pipeline**

Exosome platform
SubB2M technology

INOVIQ

Products & pipeline | Multi-stage diagnostics and therapeutics pipeline

For personal use only

TECHNOLOGY	RESEARCH TOOLS	INDICATION	USE	RESEARCH	VERIFICATION	VALIDATION	IN-MARKET
Exosomes	EXO-NET	Multiple	Pan-EV Capture	RUO			
Exosomes	NEURO-NET	Neurology	Brain Derived-EV Capture	RUO			
Exosomes	TEXO-NET	Oncology	Tumour Derived-EV Capture	RUO			
	DIAGNOSTICS	**INDICATION**	**USE**	**RESEARCH**	**ASSAY DEVELOPMENT**	**CLINICAL DEVELOPMENT**	**IN-MARKET**
hTERT	hTERT ICC[1]	Bladder Cancer	Adjunct to Cytology	IVD-CLASS 1 USA			
SubB2M	neuCA15-3	Breast Cancer	Monitoring	LDT			
SubB2M	neuCA125	Ovarian Cancer	Monitoring	LDT			
Exosomes	EXO-OC[2]	Ovarian Cancer	Screening	IVD			
	THERAPEUTICS	**INDICATION**	**USE**	**RESEARCH**	**PRE-CLINICAL**	**CLINICAL**	**APPROVAL**
Exosomes	EEV-001	Breast Cancer	Therapeutic				

***Exosome** = **EV** = Extracellular Vesicles ; **ICC** = Immunocytochemistry; **IVD** = In Vitro Diagnostic; **LDT** = Laboratory-Developed Test;*
***RUO** = Research Use Only; 1. Adjunct to urine cytology to assist the detection of bladder cancer; 2. Umbrella Research & Option Agreement with University of Queensland*

Exosomes | Significant diagnostic and therapeutic potential

For personal use only



- **Exosomes** are released by all cells and perform key roles in intercellular communication, immune regulation and disease progression:
  - Exosomes carry molecular cargo (**DNA, RNA, proteins and lipids**) that act as cell messengers or biomarkers of disease
  - Exosome biomarkers can be used to develop advanced **diagnostics**
  - Exosomes can be loaded with drugs (small molecules, RNA, other) and engineered for targeted delivery of **therapeutics**
- Significant investment by large pharma and diagnostic companies in exosome products for Oncology, Neurodegenerative, Infectious & Inflammatory diseases
- **INOVIQ's next-gen exosome platform** enables multiple applications:

Exosome isolation tools
Isolation of exosomes from blood, urine, saliva and other fluids for biomarker discovery

→

Exosome diagnostics
Utilising biomarkers for earlier detection, therapeutic selection and monitoring

→

Exosome therapeutics
Using exosomes engineered with disease-killing agents to target and treat cancer

INOVIQ

EXO-NET® | Exosome isolation products in-market and generating revenue

For personal use only

- Best-in-class **EXO-NET pan-exosome capture** (research use only) tool in-market and generating revenue
- Enables **biomarker discovery and diagnostic development**
- Offers **speed, efficiency and scalability** advantages over competitors[1]
- **Data published validating EXO-NET** utility in cancer, periodontitis, inflammatory and neurodegenerative diseases[2,3]
- Pipeline **research tools** for use in specific disease areas:
  - **NEURO-NET** for isolation of brain-derived exosomes for use in Neurodegenerative Diseases such as Alzheimer's
  - **TEXO-NET** for isolation of tumour-derived exosomes for use in Oncology

*"[INOVIQ's] new HT exosome isolation and biomarker analysis solution **solves an industry challenge** needed to commercialise exosome-based diagnostics."* [4]

Tom Livelli, Vice President, Promega

EXO-NET
PAN-EXOSOME CAPTURE

1. Appendix: Competitor comparison includes Biotechne, FUJIFILM Wako, Thermo Fisher Scientific, QIAGEN & others;
2. ISEV (ASX: 19/5/23), ANZSEV (ASX: 10/11/23) and AMP (12/11/23); 3. Immunoaffinity-enriched salivary small extracellular vesicles in periodontitis (oaepublish.com); 4. Promega EXO-NET Co-marketing Agreement (ASX: 6/7/23)

Promega INOVIQ

EXO-NET | Commercial partnerships driving revenue

For personal use only

July 2023

Promega

Co-Marketing agreement for EXO-NET products worldwide[1]

Leading provider of innovative technologies, tools and technical support to the global life sciences industry. Based in US and generating revenues of >US$700m. Established global sales, marketing and distribution capabilities across academia, clinical Laboratories/hospitals and pharma/biotech with branches in 16 countries.

Agreement to co-market EXO-NET with Promega Nucleic Acid purification systems worldwide. Expected to be major driver of future revenues.

Sep 2023

ResearchDX
The Contract Diagnostics Organization™

Licence agreement for provision of EXO-NET services in US[2]

Leading Contract Diagnostics Organisation based in US.

Agreement to use EXO-NET to provide diagnostics development services to its biotech and pharma customers.

Dec 2023

Collaboration with European Biotech for development of exosome diagnostic[3]

Biotech developing and commercialising targeted therapeutics for cancer.

Fee-for-service agreement to evaluate EXO-NET to develop exosome diagnostic for treatment selection and/or monitoring of a targeted therapy.

1. Promega EXO-NET Co-marketing Agreement (ASX: 6/7/23); 2. ResearchDx EXO-NET Services Licence (ASX 5/9/23). 3. Appendix 4C & Quarterly Business Update (ASX: 31/1/24)

INOVIQ

Lead exosome diagnostic | Ovarian Cancer screening test

For personal use only

Ovarian Cancer	• #8 cancer in women & **deadliest gynaecological cancer** • 314k new cases of ovarian cancer worldwide pa[1] • 0.25% of population has Hereditary Breast and Ovarian Cancer syndrome[2]
Unmet Medical Need	• **No approved test for early detection** of ovarian cancer in asymptomatic, average-risk women[3] • **Earlier and more accurate tests** required for screening high-risk women[3]
Market Potential	• **US$323m TAM** based on 538k tests pa @$600/test for OC high-risk screening twice yearly in US, EU5 and AU[4] • **US$32b TAM** based on 54.8m tests pa @$600/test for OC average-risk screening biennially in US, EU5 and AU[4]
Disruptive Technology	• **EXO-NET** technology enables isolation of exosomes for earlier and more accurate cancer detection • Multi-marker algorithm validated in a 450 sample retrospective case-control study with over **90% accuracy** for detection of stage I / II ovarian cancer[5]
Intended Use	• **Screening** to detect ovarian cancer in asymptomatic, high-risk women aged over 35 years
Go-to-Market Strategy	• IVD-MIA (PMA process) with US FDA • Potential **licensing deal** with large diagnostics / laboratory company

Development Path

Feasibility	Completed
Assay development	Ongoing
Plasma-serum equivalence	Completed
Biomarker validation study	Commence 1H24
Analytical & Clinical validation	Commence 1H25
IDE application	2026
Approval	2029

***IVD-MIA** = In Vitro Diagnostic Multivariate Index Assay; **PMA** = Pre-Market Approval; 1. Cancer Today (iarc.fr); 2. Ovarian Cancer Diagnostics Market Size Worth US$ 1.8 Bn by (globenewswire.com) 3. HBOC Review 0.25% population (nih.gov); 4. See Appendix, OC Diagnostic Market Potential.; 5. University of Queensland OCRF-7 data (ASX: 1/4/22)*

The University Of Queensland AUSTRALIA

INOVIQ

Exosome therapeutics | In development for solid tumours

For personal use only

- INOVIQ is developing **weaponised exosomes** engineered to target and treat solid tumours
- Utilises proprietary **EXO-ACE technology** for large-scale isolation of exosomes for therapeutic use
- In vitro **Proof-of Concept established in breast cancer cells** showing >75% cancer cell death
- Further **in vitro and in vivo studies** (animal) planned in CY24 and CY25
- Potential **advantages over autologous CAR-T/NK cell therapies** (manufacturing, stability, safety[1] and efficacy) for treatment of solid tumours





>80% recovery & >95% purity of exosomes



>75% kill rate for breast cancer cells in laboratory studies

1. US FDA investigating safety risks of CAR-T therapies using viral vectors (23/11/23) and requirement for a boxed warning on the risk of secondary T-cell malignancies (22/1/24)

INOVIQ

SubB2M tests for Cancer Monitoring

For personal use only

INOVIQ is developing solutions for non-invasive, earlier and more accurate tests for cancer monitoring

US$6.1b
Breast and Ovarian Cancer diagnostics market

	Breast Cancer	Ovarian Cancer
Background	• **#1 cancer in women** • 2.3m new cases of breast cancer worldwide pa[1] • 7.8m survivors (5-year)[1] • **10-40% of breast cancers recur within 5 years**	• #8 cancer in women, **deadliest gynaecological cancer** • 314k new cases worldwide pa[1] • 823k survivors (5-year)[1] • **50% of ovarian cancers recur within 5 years**
Market Potential	• US$4.3b global breast cancer diagnostics market[2] • **US$668m TAM[4]**	• US$1.8b global ovarian cancer diagnostics market[3] • **US$55m TAM[5]**
Disruptive Technology	• **SubB2M technology** enables detection of glycoproteins to improve cancer specificity and sensitivity • **81% sensitivity and 93% specificity** for BC detection	• Assay development and validation of SubB2M CA125 test underway
Use	• Aid in **monitoring** breast cancer treatment response & recurrence	• Aid in **monitoring** ovarian cancer treatment response & recurrence
Go-to-Market Strategy	• **LDT** then IVD (510k / PMA process) • Partner with CLIA-accredited laboratory • Potential **licensing deal** with large diagnostic / laboratory company	• **LDT** then IVD (510k / PMA process)

1. https://gco.iarc.fr/today/home
2. Breast Cancer Diagnostics Market Size & Share Report 2030 (grandviewresearch.com)
3. Ovarian Cancer Diagnostics Market Size Worth US$ 1.8 Bn by 2026 (globenewswire.com)
4. Based on 4.5m tests pa @$150/test for BC monitoring in US, EU5 and AU
5. Based on 365k tests pa @$150/test for OC monitoring in US, EU5 and AU

INOVIQ

SubB2M Breast Cancer clinical data | Outperformed leading CA15-3 test

For personal use only

Clinical Validation Study (2023)[1] | detected all stages

Retrospective, case-control, **clinical validation study** (n=483)

- ✓ Demonstrated **SubB2M CA15-3 test detected breast cancer across all stages** with high accuracy
- ✓ Detected invasive ductal (IDC) and lobular (ILC) **breast cancer types**
- ✓ **Significantly outperformed a leading CA15-3 test** (Roche Elecsys® CA15-3 II)

Monitoring Study (2024)[2] | detected different subtypes and correctly identified 19% more cancers

Retrospective, longitudinal, 2-arm **monitoring study** (n=277) to evaluate SubB2M CA15-3 test for **monitoring breast cancer** compared to Roche Elecsys® CA15-3 II (comparator)

- ✓ **Subtype arm** in pre-treatment samples (n=159) across 3 breast cancer subtypes (HR+, HER2+ and TNBC)[3] detected all breast cancer subtypes
- ✓ **Monitoring arm** in women (n=12) serially evaluated across up to 5 timepoints established equivalence for BC monitoring
- ✓ Overall, SubB2M test **outperformed** the comparator by correctly identifying 19% more histologically confirmed breast cancers
- ✓ **Concluded** SubB2M test effective for breast cancer monitoring

SubB2M CA15-3 vs Leading Existing Test

Breast Cancer All Stages	SubB2M CA15-3	Roche Elecsys CA15-3 II
AUC	0.93	0.70
sensitivity	81%	37%
specificity	93%	88%
false negative rate	19%	63%
false positive rate	7%	12%
overall accuracy	87%	63%

Test Sensitivity by stage @95% Specificity



Breast cancer (n=241: I=75, II=72, 3=72, III=72, IV = 22) and healthy controls (n=242)

1. SubB2M/CA15-3 clinical validation results (ASX: 27/6/23) ; 2. Breast cancer monitoring study results (ASX: 22/2/24); 3. HR+ = Hormone Receptor, HER2+ = Human Epidermal growth factor Receptor 2 (HER2), Triple-Negative Breast Cancer (TNBC)

Path-to-Market for SubB2M Breast & Ovarian Cancer monitoring tests

For personal use only

Activity	CY2024	CY2025	CY2026
Assay Development			
Analytical validation			
Clinical validation (I-IV)			
Monitoring study			
Real-world data			
Partner engagement			
CLIA Lab validation			
In-market			
Publications			
Conference presentations			

BC Monitoring
OC Monitoring

- SubB2M **BC monitoring study** successfully completed Feb-24
- Engagement with potential **US clinical laboratory partners** to commercialise as LDT
- Additional in-clinic studies for **real-world data** to support clinical adoption
- Conference **presentations and publications** of SubB2M data
- BC monitoring test expected **in-market** 1H25 and OC monitoring test 1H26
- Future clinical studies to gain **IVD regulatory approval** in US, Europe and Australia within 3 years

***CLIA** = Clinical Laboratory Improvement Amendments (high-complexity tests); **IVD** = In Vitro Diagnostic; **LDT** = Laboratory-Developed Test*

INOVIQ

Summary | Positioned for growth

For personal use only

- Proprietary **exosome platform** with applications across research, diagnostics and therapeutics
- **Commercial partners secured** for EXO-NET to drive revenue growth
- **Fee-for-service** exosome isolation & biomarker discovery linked to potential diagnostics development
- Advancing clinically validated **SubB2M BC test** towards commercialisation as LDT
- Progressing **pipeline** of research tools, diagnostics and therapeutics
- **Board and management** focused on execution and commercial outcomes

1. As at 5 Apr 2024; 2. Cash at 31 Dec 2023 (ASX: 31 Jan 2024)

Future milestones

For personal use only

	CY 2024	CY 2025
Exosome program	• Commercial sales of **EXO-NET** • Agreement with Pharma/Biotech for development of **exosome diagnostic** • Validation data for **NEURO-NET** isolation of brain-derived exosome biomarkers in neurodegenerative disease • Biomarker validation data for **EXO-OC** screening test • *In vitro* data for **exosome therapeutic** in multiple cancers	• Commence development and validation of **exosome diagnostic** for early detection of Alzheimer's Disease • Commence analytical and clinical validation of **EXO-OC test** for screening ovarian cancer in high-risk women • *In vivo* data for **exosome therapeutic** in breast/other cancers
SubB2M program	✓ Data from **SubB2M breast cancer** monitoring study • Secure US **Laboratory partner** for SubB2M tests (LDTs)	• First sales of **SubB2M breast cancer** monitoring test • Data from **SubB2M ovarian cancer** clinical validation study to evaluate accuracy across all stages • Real-world data from **SubB2M breast cancer** in-clinic monitoring study compared to approved CA15-3 test

Future milestones are forward-looking and may change based on study results, funding, partnering and priorities.